All News

Brain tumor patients receiving standard radiation therapy must wait up to 10 weeks for follow-up CT or MR to determine whether the treatment is working, based on the established MacDonald criteria for assessing treatment.

After 17 years, I am stepping down as editor of Oncology News International to enjoy a long-awaited retirement. When ONI was first introduced back in 1991, it represented a new concept in cancer news publications-rather than simply summarizing journal articles, we actually attended meetings all over the country and reported the results of major presentations.

The difficulty of manufacturing new chemotherapeutic agents-particularly specially formulated biologic cytotoxins-escalates the financial outlay that must be made by physicians as well as driving up the cost of drug delivery to patients, said Howard A. Burris III, MD, chief medical officer and director of drug development at the Sarah Cannon Research Institute and associate with Tennessee Oncology, both in Nashville.

New labeling for Aranesp and Procrit will tighten the use of both medications in cancer patients. The Food and Drug Administration ordered Amgen of Thousand Oaks, California to make changes to the prescribing information for its anemia drug darbepoetin alfa (Aranesp). Johnson & Johnson’s Ortho Biotech had already accepted the changes for the labeling of its ESA epoetin alfa (Procrit).

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain.

The US Department of Veterans Affairs has selected the American College of Radiology to accredit 33 VA hospital radiation oncology facilities nationwide.

Cetuximab (Erbitux) has received broader approval in the European Union as a first-line treatment for metastatic colorectal cancer.

In today’s healthcare environment, physicians are compensated for the volume of services rendered as well as ancillary services (MRI, PET, CT, catheterization, and other test orders).

Only in Hollywood can New Orleans stand in for Los Angeles while a suave crooner portrays a serious scientist.

The lead investigator in an evaluation of bevacizumab (Avastin) combined with sunitinib malate (Sutent) for renal cell carcinoma (RCC) said the project would be abandoned. FDA issued a product safety alert after Genentech, Avastin’s developer, reported serious complications in several patients enrolled in the phase I trial.

Polypharmacy, defined as concurrent use of several drugs, is not uncommon in the elderly and increases their risk of adverse drug reactions and interactions.[1] Besides adverse drug reactions and drug-drug interactions, other clinical sequelae of polypharmacy include nonadherence, increased risk of hospitalizations, and medication errors.

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc, recently announced that The New England Journal of Medicine published results of a phase III trial demonstrating that sorafenib (Nexavar) tablets decreased the absolute risk of death by 31% in patients with unresectable hepatocellular carcinoma (HCC) vs patients who received placebo. This represents a 44% improvement in median overall survival for patients treated with sorafenib.

There are a plethora of websites that hawk miracle cancer cures, luring consumers in with seductive testimonials of instant good health. To the average person, these sites are dubious at best. But for some cancer patients, the promise of an easy panacea veers on dangerous.

As a boy growing up in the Jim Crow South, LaSalle Leffall, Jr., MD, lifted himself above that era’s stifling segregation by embracing his father’s rock-solid credo: With a good education and hard work, combined with honesty and integrity, there are no boundaries.

A common conundrum that community oncologists face in their practices is whether to bill a first encounter with a new patient referred by another physician as a consultation or as a new patient visit. Making the distinction may seem like splitting hairs, but the Centers for Medicare and Medicaid Services (CMS) has very specific billing criteria on this issue.

Annually, adverse drug reactions (ADRs) result in costs of $3.6 billion and 140,000 deaths.1 Yet in 2005, only 15,107 reports of fatalities linked to potential drug toxicity were reported to the US Food and Drug Administration.2 This low number suggests that, despite significant morbidity and morality, ADRs remain underappreciated by clinicians. This is particularly troublesome when it comes to ADRs associated with oncology drugs.

Radiation is often considered immunosuppressive, an activity that is most likely a result of the complex interplay of hormesis and the abscopal effect. The abscopal effect, also called the “distant bystander” effect, is a paradoxical effect of radiation on cellular systems whereby local radiation may have an antitumor effect on tumors distant from the site of radiation.

CHICAGO-Sunday, June 1 marked the 15th annual Cancer Survivors’ Celebration and Walk, sponsored by the Robert H. Lurie Cancer Center of Northwestern University as part of National Cancer Survivors Day. More than 800 cancer survivors participated in the walk (see photograph).

This review focuses on discussing the efficacy and cardiotoxicity of anthracycline and trastuzumab combination regimens compared to nonanthracycline and trastuzumab regimens.

Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.

Long-term survivors of testicular cancer treated with cisplatin-based chemotherapy have evidence of endothelial injury and dysfunction, compared with those who did not receive chemotherapy, according to a University of Pennsylvania study (Cancer 112:1949-1953, 2008).

RCELONA-Colon cancer patients who received oral capecitabine (Xeloda) after surgery had significantly better 5-year survival rates than those given IV 5-FU/LV chemotherapy, according to a preplanned multivariate analysis of the X-ACT trial data presented at the 2008 World Congress on Gastrointestinal Cancer (Twelves et al: poster 0-033).

UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.

In May 2008, ONI reviewed an article by Herman Suit, MD, and colleagues in which they argued that randomized trials of proton beam therapy vs standard radiotherapy are not needed prior to a wider use of proton beam therapy. In an ONI reader poll, 81% disagreed with Dr. Suit, as does Dr. Robert Parker, of SUNY Stony Brook, in his letter below.

The authors of this article accomplished their goal to provide an overview of physical long-term / late effects. Similar to most available literature published since the Institute of Medicine report in November 2005, it provided a descriptive summary of the epidemiologic data. While vital to increasing the knowledge base of nurses on the frontlines, it provides little guidance as to how to change or improve practice.

In cancer treatment these days, the immediate-what needs to be done for the patient right now toward achieving long-term survival-is coupled with planning post-treatment surveillance, care, and support for patients who will likely survive their disease.

Drug is indicated for rescue of normal cells following high dose methotrexate administration for osteosarcoma. It is also indicated to diminish and counteract methotrexate toxicity if the drug is not effectively eliminated, or for inadvertent overdose of folic acid antagonists.

CHICAGO-This year’s roiling political contest took center stage at ASCO 2008 in a special session that reviewed the healthcare insurance reform proposals of Sen. John McCain and Sen. Barack Obama, the presumptive presidential nominees.